CRTX News and Press, Cortexyme Inc.

Alzheimer’s drug developer Cortexyme ( NASDAQ: CRTX ) announced on Wednesday that the company would change its corporate name and ticker symbol with effect from August. Accordingly, Cortexyme ( CRTX ) will be branded as Quince Therapeutics next month, and its ti...

New ticker symbol (Nasdaq: QNCX) to initiate trading on August 1, 2022 Cortexyme, Inc. (Nasdaq: CRTX) today announced that the company’s planned corporate name change to Quince Therapeutics is expected take effect on Monday, August 1, 2022. In conjunction with the cor...

Once daily dose of COR588 over 10-day period well-tolerated with no serious adverse events observed Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today reported the successful ...

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today announced new preclinical data demonstrating the efficacy of the company’s 3CLpro inhibitor, COR803, for treatment of coronavirus...

Gainers: Cortexyme (CRTX) +7.9%. GoodRx Holdings (GDRX) +5.4%. Concert Pharmaceuticals (CNCE) +4.9%. Roku (ROKU) +4.3%. Mercer International (MERC) +4.3%. Losers: Rhythm Pharmaceuticals (RYTM) -8.5%. Redbox Entertainment (RDBX) -3.6%. KemPharm (KMPH) -3.1%. SS&C Technologies Hol...

A group of low cap biotechs are leading a selloff among Alzheimer’s drug developers after Roche (OTCQX:RHHBY) (OTCQX:RHHBF) announced on Thursday that their experimental drug for the memory robbing disease did not meet key goals in a mid-stage trial. Developed by the fellow Swiss biote...

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on rare and degenerative diseases, today announced the appointment of June Bray, a pharmaceutical industry veteran and global drug development and regulatory process expert, to the company’s Board ...

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the appointment of Dr. Philip S. Low, a renowned targeted drug discovery researcher and vet...

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company developing therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the completion of its acquisition of Novosteo, a privately-held biotech company focused on ...

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, announced that the company will participate at The 4 th International Conference on Porphyromonas g...